Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

The Drugs industry as a whole closed the day up 0.1% versus the S&P 500, which was unchanged. Laggards within the Drugs industry included China Pharma ( CPHI), down 4.1%, ImmuCell ( ICCC), down 6.8%, Tianyin Pharmaceutical ( TPI), down 2.1%, Acura Pharmaceuticals ( ACUR), down 1.7% and Can Fite Biofarma ( CANF), down 4.0%.

TheStreet Ratings Group would like to highlight 3 stocks that pushed the industry lower today:

Can Fite Biofarma ( CANF) is one of the companies that pushed the Drugs industry lower today. Can Fite Biofarma was down $0.11 (4.0%) to $2.64 on light volume. Throughout the day, 3,910 shares of Can Fite Biofarma exchanged hands as compared to its average daily volume of 13,800 shares. The stock ranged in price between $2.61-$2.72 after having opened the day at $2.61 as compared to the previous trading day's close of $2.75.

Can Fite Biofarma has a market cap of $23.5 million and is part of the health care sector. Shares are down 56.9% year-to-date as of the close of trading on Monday. Currently there is 1 analyst who rates Can Fite Biofarma a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

At the close, Acura Pharmaceuticals ( ACUR) was down $0.01 (1.7%) to $0.56 on light volume. Throughout the day, 36,782 shares of Acura Pharmaceuticals exchanged hands as compared to its average daily volume of 65,500 shares. The stock ranged in price between $0.55-$0.58 after having opened the day at $0.55 as compared to the previous trading day's close of $0.57.

Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, researches, develops, and commercializes products to address medication abuse and misuse utilizing its proprietary Aversion and Impede technologies. Acura Pharmaceuticals has a market cap of $28.3 million and is part of the health care sector. Shares are down 65.3% year-to-date as of the close of trading on Monday. Currently there is 1 analyst who rates Acura Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates Acura Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and generally disappointing historical performance in the stock itself.

Highlights from TheStreet Ratings analysis on ACUR go as follows:

  • The company, on the basis of change in net income from the same quarter one year ago, has underperformed when compared to that of the S&P 500 and greatly underperformed compared to the Pharmaceuticals industry average. The net income has decreased by 14.5% when compared to the same quarter one year ago, dropping from -$3.08 million to -$3.52 million.
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Pharmaceuticals industry and the overall market, ACURA PHARMACEUTICALS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • ACUR's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 65.07%, which is also worse than the performance of the S&P 500 Index. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • ACURA PHARMACEUTICALS INC reported flat earnings per share in the most recent quarter. The company has reported a trend of declining earnings per share over the past two years. However, the consensus estimate suggests that this trend should reverse in the coming year. During the past fiscal year, ACURA PHARMACEUTICALS INC reported poor results of -$0.30 versus -$0.20 in the prior year. This year, the market expects an improvement in earnings (-$0.16 versus -$0.30).
  • ACUR's debt-to-equity ratio of 0.94 is somewhat low overall, but it is high when compared to the industry average, implying that the management of the debt levels should be evaluated further. Even though the debt-to-equity ratio shows mixed results, the company's quick ratio of 7.38 is very high and demonstrates very strong liquidity.

You can view the full analysis from the report here: Acura Pharmaceuticals Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

China Pharma ( CPHI) was another company that pushed the Drugs industry lower today. China Pharma was down $0.01 (4.1%) to $0.29 on light volume. Throughout the day, 22,287 shares of China Pharma exchanged hands as compared to its average daily volume of 48,700 shares. The stock ranged in price between $0.29-$0.30 after having opened the day at $0.29 as compared to the previous trading day's close of $0.30.

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. China Pharma has a market cap of $13.7 million and is part of the health care sector. Shares are down 8.7% year-to-date as of the close of trading on Monday.

TheStreet Ratings rates China Pharma as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Highlights from TheStreet Ratings analysis on CPHI go as follows:

  • CHINA PHARMA HOLDINGS INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. The company has reported a trend of declining earnings per share over the past two years. During the past fiscal year, CHINA PHARMA HOLDINGS INC swung to a loss, reporting -$0.45 versus $0.10 in the prior year.
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Pharmaceuticals industry. The net income has significantly decreased by 93.6% when compared to the same quarter one year ago, falling from -$4.46 million to -$8.64 million.
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Pharmaceuticals industry and the overall market, CHINA PHARMA HOLDINGS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • Net operating cash flow has significantly decreased to -$0.08 million or 103.94% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
  • The share price of CHINA PHARMA HOLDINGS INC has not done very well: it is down 6.46% and has underperformed the S&P 500, in part reflecting the company's sharply declining earnings per share when compared to the year-earlier quarter. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.

You can view the full analysis from the report here: China Pharma Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.